Mikael Dolsten joins Maxion's Board of Directors as Non-Executive Director

Monograph is hiring an Associate in London or San Francisco.

Backing RQ Bio’s development of long-acting influenza therapies.

Matt brings over a decade of experience in company formation and early-stage biopharma investing.

Advancing a new approach to autoimmune disease.

Following their $70M Series A, this is a strong step forward from a team executing with real focus on an unmet need.